Technical Analysis for BIIB - Biogen Idec Inc.

Grade Last Price % Change Price Change
grade C 341.24 0.69% 2.33
BIIB closed up 0.69 percent on Thursday, September 20, 2018, on 79 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical BIIB trend table...

Date Alert Name Type % Chg
Sep 20 20 DMA Resistance Bearish 0.00%
Sep 20 Stochastic Buy Signal Bullish 0.00%
Sep 20 Pocket Pivot Bullish Swing Setup 0.00%
Sep 20 Up 3 Days in a Row Strength 0.00%
Sep 19 Oversold Stochastic Weakness 0.69%
Sep 18 Lower Bollinger Band Walk Weakness 1.29%
Sep 18 Stochastic Reached Oversold Weakness 1.29%
Sep 18 Lower Bollinger Band Touch Weakness 1.29%
Sep 18 Oversold Stochastic Weakness 1.29%
Sep 17 Lower Bollinger Band Touch Weakness 2.05%

Older signals for BIIB ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Is BIIB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 388.67
52 Week Low 249.17
Average Volume 1,335,411
200-Day Moving Average 311.7595
50-Day Moving Average 346.2006
20-Day Moving Average 342.583
10-Day Moving Average 338.833
Average True Range 6.2332
ADX 14.57
+DI 19.1255
-DI 22.6331
Chandelier Exit (Long, 3 ATRs ) 337.2404
Chandelier Exit (Short, 3 ATRs ) 351.1796
Upper Bollinger Band 352.5765
Lower Bollinger Band 332.5895
Percent B (%b) 0.43
BandWidth 5.834207
MACD Line -1.2745
MACD Signal Line -0.6487
MACD Histogram -0.6258
Fundamentals Value
Market Cap 72.15 Billion
Num Shares 211 Million
EPS 15.24
Price-to-Earnings (P/E) Ratio 22.39
Price-to-Sales 5.55
Price-to-Book 5.61
PEG Ratio 2.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 348.50
Resistance 3 (R3) 348.16 345.40 347.29
Resistance 2 (R2) 345.40 343.55 345.57 346.89
Resistance 1 (R1) 343.32 342.41 344.36 343.66 346.48
Pivot Point 340.56 340.56 341.08 340.73 340.56
Support 1 (S1) 338.48 338.71 339.52 338.82 336.00
Support 2 (S2) 335.72 337.57 335.89 335.59
Support 3 (S3) 333.64 335.72 335.19
Support 4 (S4) 333.98